Sandercock Brett
Form 3
December 08, 2005

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Expires:	January 31, 2005
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Â Sandercock Brett
(Last) (First) (Middle)

17 GUINEVIERE COURT
(Street)

CASTLE HILL, NSW,Â C3Â 2154
(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/01/2005

3. Issuer Name **and** Ticker or Trading Symbol
RESMED INC [RMD]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Financial Officer

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
ResMed Common Stock	170.86	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of			

				Shares		(I) (Instr. 5)	
ResMed Options	10/02/1999 (1)	10/01/2008	ResMed Common Stock	6,000 (1) (2)	$ 5.625 (2)	D	Â
ResMed Options	07/30/2000 (1)	07/29/2009	ResMed Common Stock	8,000 (1) (2)	$ 6.6718 (2)	D	Â
ResMed Options	07/02/2002 (1)	07/01/2011	ResMed Common Stock	4,000 (1) (2)	$ 25.275 (2)	D	Â
ResMed Options	01/15/2005 (1)	01/14/2014	ResMed Common Stock	12,000 (1) (2)	$ 20.54 (2)	D	Â
ResMed Options	01/20/2006 (1)	01/19/2015	ResMed Common Stock	24,000 (1) (2)	$ 24.935 (2)	D	Â
ResMed Options	12/01/2006 (3)	11/30/2015	ResMed Common Stock	10,000 (3)	$ 40.8	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sandercock Brett 17 GUINEVIERE COURT CASTLE HILL, NSW,Â C3Â 2154	Â	Â	Â Chief Financial Officer	Â

Signatures

Brett Sandercock	12/08/2005
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Options are exercisable 1/3 each year beginning 1 year after date of grant.

(2) All figures reflect 2-for-1 stock split effective 9/30/2005

(3) Options vest 1/4 each year beginning 1 year after date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.